China Sky One Medical, Inc. Appoints Pricewaterhouse Coopers to Help Develop a SOX...

China Sky One Medical, Inc. Appoints Pricewaterhouse Coopers to Help Develop a
SOX 404 Compliance Program

HARBIN, China, May 19 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,
Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading
fully integrated pharmaceutical company producing over-the-counter drugs in
the People's Republic of China ("PRC"), today announced that it engaged
Pricewaterhouse Coopers ("PWC") to assist the Company in complying with the
financial reporting and control requirements of Sarbanes-Oxley Act Section 404
("SOX 404") by December 31, 2009.
Since the beginning of this year, China Sky One Medical has been engaged
in improving its financial reporting and internal control system and in the
selection of reputable consulting firms. As a result of this effort, PWC will
work closely with the Company's management to help prepare a SOX 404
compliance program by drawing on its experience in complying with SOX 404
requirements on an ongoing basis. As part of its compliance with SOX 404, the
Company and its external auditor will examine and report on the adequacy of
the Company's internal financial reporting and controls systems after
documenting and testing financial reporting and control procedures.
"We are pleased to engage PWC for this important undertaking as we strive
to ensure that the Company is in full compliance with SOX 404 reporting
requirements as we continue to pave the way for our long term growth," said
Mr.
Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "We are committed to
making every effort to increase shareholders' confidence in our financial
reporting and internal control standards."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company.
The Company engages in the manufacturing, marketing and distribution of
pharmaceutical, medicinal and diagnostic products. Through its wholly-owned
subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company
("TDR"), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang
Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang
Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes
over-the-counter pharmaceutical products, which make up its major revenue
source. For more information, visit http://www.skyonemedical.com .
Safe Harbor Statement
Certain of the statements made in the press release constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements can be identified by the use
of forward- looking terminology such as "believe," "expect," "may," "will,"
"should," "project," "plan," "seek," "intend," or "anticipate" or the negative
thereof or comparable terminology. Such statements typically involve risks and
uncertainties and may include financial projections or information regarding
the Company's implementation of SOX 404. Actual results could differ
materially from the expectations reflected in such forward-looking statements
as a result of a variety of factors, including the risks associated with the
effect of changing economic conditions in The People's Republic of China,
variations in cash flow, reliance on collaborative retail partners and on new
product development, variations in new product development, risks associated
with rapid technological change, and the potential of introduced or undetected
flaws and defects in products, and other risk factors detailed in reports
filed with the Securities and Exchange Commission from time to time.
For more information, please contact:

Company Contact:
China Sky One Medical, Inc.
Mr. Yu-Bo Hao, CFO
Tel: +86-451-5399-4069
Email: china_sky_one@yahoo.cn

Investor Relations Contact:
CCG Investor Relations
Mr. Crocker Coulson, President
Tel: +1-646-213-1915
Email: crocker.coulson@ccgir.com
Web: http://www.ccgirasia.com

SOURCE China Sky One Medical, Inc.

Company Contact: Mr. Yu-Bo Hao, CFO of China Sky One Medical, Inc.,
+86-451-5399-4069, or china_sky_one@yahoo.cn; or Investor Relations Contact:
Mr. Crocker Coulson, President of CCG Investor Relations, +1-646-213-1915, or
crocker.coulson@ccgir.com